PYC Therapeutics Advances RNA Pipeline with $600M Capital and Clinical Milestones

Capital Raise Fuels Ambitious Clinical Development

PYC Therapeutics Ltd (ASX:PYC) closed FY2026 with a fortified balance sheet following a substantial $600 million capital raise early in the year, securing its operational runway through to 2030. This financial boost welcomed a syndicate of global life sciences investors, underpinning the company’s ambition to advance its RNA therapeutic pipeline targeting rare genetic diseases.

The capital injection complements PYC’s strategic focus on delivering critical human safety and efficacy data across four lead programs, Polycystic Kidney Disease (PKD), Phelan-McDermid Syndrome (PMS), Autosomal Dominant Optic Atrophy (ADOA), and Retinitis Pigmentosa type 11 (RP11), that are poised to transition into registrational trials.

Clinical Progress Across Four Genetic Disease Programs

The PKD program (PYC-003) advanced from Phase 1a single ascending dose studies in healthy volunteers and PKD patients into a Phase 1b multiple ascending dose trial. The ongoing study aims to establish clinical proof of concept by demonstrating safety, tolerability, and efficacy markers such as biomarker responses and kidney function metrics. To date, no treatment-related serious adverse events have been reported, and preclinical data show promising gene expression and cyst volume reduction in patient-derived models.

Meanwhile, the PMS program (PYC-002) made strides through preclinical development, including dose-range finding and Good Laboratory Practice toxicology studies. Supported by encouraging pharmacokinetic and pharmacodynamic data in non-human primates, PYC anticipates initiating first-in-human clinical trials in 2027, targeting a disease with no current treatment options and an estimated $5 billion addressable market.

In ophthalmology, PYC-001 for ADOA progressed into a Phase 1b multiple ascending dose study, with data revealing a favourable safety profile and early signs of efficacy, including sustained improvements in visual acuity and reduced retinal stress. Non-human primate studies support the potential for extended dosing intervals, which could enhance patient convenience and treatment adherence.

VP-001 for RP11 continued clinical evaluation through an open-label extension study, with longer-term data demonstrating clinically meaningful improvements in low-luminance visual acuity. Regulatory engagement with the FDA has yielded alignment on registrational study design, positioning the program for potential late-stage clinical development.

Financials Reflect Investment in Growth

Despite a net loss of $43.8 million for FY2026, down from $51.0 million the previous year, PYC increased its research and development expenditure to $74 million, reflecting the advancing clinical programs. General and administrative costs rose to $9.4 million, partly due to higher share-based payments and professional services. The company held $53.6 million in cash and equivalents at year-end, supplemented by $350 million in term deposits and $265 million in financial assets, underscoring a robust liquidity position.

The company’s financial statements also report a $26 million R&D tax incentive income, up from $23.5 million in FY2025, supporting ongoing investment in innovation. The strengthened financial position provides flexibility to navigate the inherently risky and capital-intensive biotech development landscape.

Governance and Leadership Updates

Peter Coleman, appointed Chair in November 2025, brings extensive global leadership experience from his tenure at Woodside Energy and roles on major corporate boards. Alongside CEO Dr Rohan Hockings and newly appointed Non-Executive Director Professor Ian Constable, the Board is focused on scaling executive and operational capabilities to support clinical milestones and eventual commercialisation.

In line with company growth, executive remuneration arrangements were reviewed and updated to align with strategic objectives and shareholder interests, including long-term incentive awards for Dr Hockings subject to shareholder approval.

Risks and Outlook

PYC acknowledges the inherent risks in drug development, including regulatory approvals, clinical trial recruitment, and competitive pressures. The company actively manages these through rigorous preclinical validation, regulatory engagement, and a diversified pipeline approach.

As PYC moves toward registrational trials, the market will be watching for upcoming clinical data readouts expected over the next 12 to 24 months, which will be pivotal in shaping the company’s development trajectory and commercial prospects.